Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningitis; Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections; Meningococcal meningitis
- Focus Pharmacodynamics; Registrational
- Sponsors sanofi pasteur
- 28 Jun 2017 Planned End Date changed from 1 Mar 2017 to 20 Dec 2017.
- 28 Jun 2017 Planned primary completion date changed from 1 Mar 2017 to 20 Dec 2017.
- 28 Jun 2017 Status changed from completed to active, no longer recruiting.